Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Effectiveness of Pulmicort Respules (Budesonide Inhalation Suspension) Versus SINGULAIR (Montelukast Sodium) in Children 2-8 Years Old With Asthma Requiring Controller Therapy.

NCT00641472 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00641472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00641472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Effectiveness of Pulmicort Respules (Budesonide Inhalation Suspension) Versus SINGULAIR (Montelukast Sodium) in Children 2-8 Years Old With Asthma Requiring Controller Therapy.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2002
Completion date
February 28, 2005
Enrollment
380 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma